Johnson & Johnson
5 articles
Industry NewsJohnson & Johnson / Ollin BiosciencesEndpoints News
J&J Pays Up to $3.3B for Ollin to Fill Its Retina Gap
- Johnson & Johnson will acquire Ollin Biosciences for roughly $2.2B upfront plus up to about $1.1B in regulatory and commercial milestones; closing is expected by year-end.
- Ollin's lead, OLN324, is a bispecific antibody for diabetic macular edema and wet AMD; the company says an early head-to-head study beat Roche's Vabysmo on anatomy and vision.
- A separate Blackstone Life Sciences agreement provides $750M of multi-year funding for late-stage development, in exchange for payments and royalties.
J&J has contact lenses and surgical vision but no retinal drug, so it is buying its way into the Vabysmo/Eylea market rather than building there. Note that the Blackstone money sits outside the headline price: the real net cost and the royalty drag depend on terms we can't see. The pitch rests on Ollin's own cross-study claim against Vabysmo, and the dosing interval, not just efficacy, will decide whether retinal specialists switch.
Industry NewsJohnson & JohnsonJohnson & Johnson
J&J's Caplyta Repeats Its Bipolar Mania Win in a Second Phase 3
- J&J said its second pivotal Phase 3 of Caplyta (lumateperone) in acute bipolar mania met the primary and key secondary endpoints.
- The first study read out in September; together they are intended to support a US submission for mania.
- Both trials ran three weeks, so maintenance efficacy and long-term safety are not addressed.
Two positive pivotal trials is what the FDA wants, and the second effect size was smaller than the first, which is worth noting for a label negotiation. Caplyta is a key piece of the Intra-Cellular deal, so this expands the addressable psychiatric market inside a crowded atypical-antipsychotic class. Differentiation will rest on tolerability versus metabolic burden rather than raw efficacy.
Industry NewsJohnson & Johnson / Protagonist TherapeuticsBioSpace
J&J and Protagonist's Icotyde improves psoriatic arthritis, but Skyrizi likely to stay ahead
- Phase 3 ICONIC-PsA 1 met its primary endpoint: 58% of Icotyde patients reached ACR20 at week 16 versus 41% on placebo, with no new safety signals reported by J&J.
- BMO put placebo-adjusted joint improvement at 17% versus 23% for Skyrizi in KEEPsAKE 1, saying this does not establish differentiation.
- BMO sees oral convenience driving uptake and expects long-term share gains; Icotyde was approved for plaque psoriasis in March 2026.
Cross-trial comparisons are shaky, but a smaller placebo-adjusted gain than Skyrizi means Icotyde cannot win on joint efficacy. Its pitch is convenience: the first oral IL-23R peptide against an injectable incumbent. For J&J, which also sells Tremfya, the question is whether pill preference outweighs a visible efficacy gap.
Industry NewsJohnson & JohnsonEndpoints News
FDA Gives J&J's Rybrevant Faspro Accelerated Approval in Head and Neck Cancer
- The FDA granted accelerated approval to subcutaneous amivantamab (Rybrevant Faspro) for recurrent or metastatic head and neck squamous cell carcinoma that progressed after platinum chemotherapy and a PD-(L)1 antibody; HPV-associated oropharyngeal disease is excluded.
- It rests on a single-arm cohort of the Phase 1b/2 OrigAMI-4 study, with confirmatory trials required; the FDA called it the first new drug for this setting in a decade.
This is the first indication outside lung cancer for the EGFR/MET bispecific, and a single-arm response-rate approval means the Phase 3 OrigAMI-5 first-line study now carries the franchise's credibility. Cetuximab remains the comparator everyone will cite; with no randomized data, the open question is how much of the response translates into survival.
Industry NewsJohnson & Johnson / Halda TherapeuticsBioSpace
J&J's Halda-born RIPTAC hits 75% response in late-line prostate cancer
- J&J's oral RIPTAC JNJ-6143, inherited with its roughly $3 billion Halda purchase, posted a 75% confirmed response rate (12 of 16 measurable-disease patients) in Phase 1 data at ESMO.
- Patients had heavily pretreated metastatic castration-resistant prostate cancer, with a median of four prior therapies.
- A 50 mg daily dose was chosen, with nausea and raised lipids most common; Phase 2 is planned.
Twelve responders out of sixteen is a striking line, but it is a small, early Phase 1 cut. The more useful point is for J&J's roughly $3 billion Halda purchase: a 75% response in patients with a median of four prior therapies makes Phase 2 the real test of whether this oral RIPTAC can anchor a prostate franchise.